<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34361021</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>15</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8255</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22158255</ELocationID><Abstract><AbstractText>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the COVID-19 pandemic. Patients may present as asymptomatic or demonstrate mild to severe and life-threatening symptoms. Although COVID-19 has a respiratory focus, there are major cardiovascular complications (CVCs) associated with infection. The reported CVCs include myocarditis, heart failure, arrhythmias, thromboembolism and blood pressure abnormalities. These occur, in part, because of dysregulation of the Renin-Angiotensin-Aldosterone System (RAAS) and Kinin-Kallikrein System (KKS). A major route by which SARS-CoV-2 gains cellular entry is via the docking of the viral spike (S) protein to the membrane-bound angiotensin converting enzyme 2 (ACE2). The roles of ACE2 within the cardiovascular and immune systems are vital to ensure homeostasis. The key routes for the development of CVCs and the recently described long COVID have been hypothesised as the direct consequences of the viral S protein/ACE2 axis, downregulation of ACE2 and the resulting damage inflicted by the immune response. Here, we review the impact of COVID-19 on the cardiovascular system, the mechanisms by which dysregulation of the RAAS and KKS can occur following virus infection and the future implications for pharmacological therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Membrane Proteins and Receptors (COMPARE), School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Eleanor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Sophie R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslop</LastName><ForeName>Calum R A</ForeName><Initials>CRA</Initials><Identifier Source="ORCID">0000-0001-6066-3410</Identifier><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Pirathini</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohanraj</LastName><ForeName>Gearry G J</ForeName><Initials>GGJ</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidow</LastName><ForeName>Hamza A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Rory C P</ForeName><Initials>RCP</Initials><AffiliationInfo><Affiliation>School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-4424-239X</Identifier><AffiliationInfo><Affiliation>Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Membrane Proteins and Receptors (COMPARE), School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolard</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5406-6847</Identifier><AffiliationInfo><Affiliation>Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Membrane Proteins and Receptors (COMPARE), School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/N020081/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>S8TIM42R2W</RegistryNumber><NameOfSubstance UI="D001920">Bradykinin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001920" MajorTopicYN="N">Bradykinin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016234" MajorTopicYN="Y">Kallikrein-Kinin System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="Y">Renin-Angiotensin System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cardiovascular system</Keyword><Keyword MajorTopicYN="N">kinin&#x2013;kallikrein system</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">renin&#x2013;angiotensin&#x2013;aldosterone system</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34361021</ArticleId><ArticleId IdType="pmc">PMC8347967</ArticleId><ArticleId IdType="doi">10.3390/ijms22158255</ArticleId><ArticleId IdType="pii">ijms22158255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2013;1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard with Vaccination Data.  [(accessed on 30 June 2021)]; Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E. A comprehensive review of COVID-19 characteristics. Biol. Proced. Online. 2020;22:19. doi: 10.1186/s12575-020-00128-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12575-020-00128-2</ArticleId><ArticleId IdType="pmc">PMC7402395</ArticleId><ArticleId IdType="pubmed">32774178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas C., Delobel P., de Souto Barreto P., Izopet J. COVID-19, Virology and Geroscience: A Perspective. J. Nutr. Health Aging. 2020;24:685&#x2013;691. doi: 10.1007/s12603-020-1416-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-020-1416-2</ArticleId><ArticleId IdType="pmc">PMC7301052</ArticleId><ArticleId IdType="pubmed">32744561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802&#x2013;810. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V.O., Carerj M.L., Wieters I., Fahim M., Arendt C., Hoffmann J., Shchendrygina A., Escher F., Vasa-Nicotera M., Zeiher A.M., et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265&#x2013;1273. doi: 10.1001/jamacardio.2020.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir. Med. 2021;9:129. doi: 10.1016/S2213-2600(21)00031-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. COVERSCAN study investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020;12:8. doi: 10.1038/s41368-020-0074-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41368-020-0074-x</ArticleId><ArticleId IdType="pmc">PMC7039956</ArticleId><ArticleId IdType="pubmed">32094336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., Huan Y., Yang P., Zhang Y., Deng W., et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875&#x2013;879. doi: 10.1038/nm1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudit G.Y., Kassiri Z., Jiang C., Liu P.P., Poutanen S.M., Penninger J.M., Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Investig. 2009;39:618&#x2013;625. doi: 10.1111/j.1365-2362.2009.02153.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2009.02153.x</ArticleId><ArticleId IdType="pmc">PMC7163766</ArticleId><ArticleId IdType="pubmed">19453650</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020;5:562&#x2013;569. doi: 10.1038/s41564-020-0688-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0688-y</ArticleId><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyrou I., Randeva H.S., Spandidos D.A., Karteris E. Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19. Signal Transduct. Target Ther. 2021;6:21. doi: 10.1038/s41392-020-00460-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00460-9</ArticleId><ArticleId IdType="pmc">PMC7812344</ArticleId><ArticleId IdType="pubmed">33462185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikellis C., Thomas M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. 2012;2012:256294. doi: 10.1155/2012/256294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/256294</ArticleId><ArticleId IdType="pmc">PMC3321295</ArticleId><ArticleId IdType="pubmed">22536270</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche J.A., Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. 2020;34:7265&#x2013;7269. doi: 10.1096/fj.202000967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202000967</ArticleId><ArticleId IdType="pmc">PMC7267506</ArticleId><ArticleId IdType="pubmed">32359101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021;93:250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocaranza M.P., Riquelme J.A., Garc&#xed;a L., Jalil J.E., Chiong M., Santos R.A.S., Lavandero S. Counter-regulatory renin&#x2013;angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 2020;17:116&#x2013;129. doi: 10.1038/s41569-019-0244-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-019-0244-8</ArticleId><ArticleId IdType="pmc">PMC7097090</ArticleId><ArticleId IdType="pubmed">31427727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks M.A., Crowley S.D., Gurley S.B., Mirotsou M., Coffman T.M. Classical Renin-Angiotensin system in kidney physiology. Compr. Physiol. 2014;4:1201&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137912</ArticleId><ArticleId IdType="pubmed">24944035</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006;86:747&#x2013;803. doi: 10.1152/physrev.00036.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00036.2005</ArticleId><ArticleId IdType="pubmed">16816138</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski C., Lenehan P., Puranik A., Agarwal V., Venkatakrishnan A.J., Niesen M.J.M., O&#x2019;horo J.C., Badley A.D., Halamka J., Soundararajan V. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. medRxiv. 2021 doi: 10.1101/2021.02.15.21251623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.15.21251623</ArticleId><ArticleId IdType="pmc">PMC8238652</ArticleId><ArticleId IdType="pubmed">34223401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., da Costa J., Zhang L., Pei Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822&#x2013;828. doi: 10.1038/nature00786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature00786</ArticleId><ArticleId IdType="pubmed">12075344</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000;87:E1&#x2013;E9. doi: 10.1161/01.RES.87.5.e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.87.5.e1</ArticleId><ArticleId IdType="pubmed">10969042</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.Y., Li L., Zhang Y., Wang X.S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty. 2020;9:45. doi: 10.1186/s40249-020-00662-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00662-x</ArticleId><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M.K., Karnik S., Saef J., Bergmann C., Barnard J., Lederman M.M., Tilton J., Cheng F., Harding C.V., Young J.B., et al. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine. 2020;58:102907. doi: 10.1016/j.ebiom.2020.102907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102907</ArticleId><ArticleId IdType="pmc">PMC7415847</ArticleId><ArticleId IdType="pubmed">32771682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Guo L., Huang L., Zhang C., Luo R., Zeng L., Liang H., Li Q., Lu X., Wang X., et al. Distinct disease severity between children and older adults with COVID-19: Impacts of ACE2 expression, distribution, and lung progenitor cells. Clin. Infect. Dis. 2021;3:ciaa1911. doi: 10.1093/cid/ciaa1911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1911</ArticleId><ArticleId IdType="pmc">PMC7799282</ArticleId><ArticleId IdType="pubmed">33388749</ArticleId></ArticleIdList></Reference><Reference><Citation>Glowacka I., Bertram S., Herzog P., Pfefferle S., Steffen I., Muench M.O., Simmons G., Hofmann H., Kuri T., Weber F., et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 2010;84:1198&#x2013;1205. doi: 10.1128/JVI.01248-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01248-09</ArticleId><ArticleId IdType="pmc">PMC2798380</ArticleId><ArticleId IdType="pubmed">19864379</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook J.R., Ausiello J. Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19. Rev. Endocr. Metab. Disord. 2021 doi: 10.1007/s11154-021-09663-z. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-021-09663-z</ArticleId><ArticleId IdType="pmc">PMC8245275</ArticleId><ArticleId IdType="pubmed">34195965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y., Zhang J., Schiavon C.R., He M., Chen L., Shen H., Zhang Y., Yin Q., Cho Y., Andrade L., et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ. Res. 2021;128:1323&#x2013;1326. doi: 10.1161/CIRCRESAHA.121.318902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318902</ArticleId><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrosa M.A., Valenzuela R., Garrido-Gil P., Labandeira C.M., Navarro G., Franco R., Labandeira-Garcia J.L., Rodriguez-Perez A.I. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin. Sci. 2021;135:465&#x2013;481. doi: 10.1042/CS20201511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20201511</ArticleId><ArticleId IdType="pmc">PMC7851407</ArticleId><ArticleId IdType="pubmed">33479758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui Y., Li J., Venzon D.J., Berzofsky J.A. SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells from Macaque Lung Bronchoalveolar Lavage. Front. Immunol. 2021;12:658428. doi: 10.3389/fimmu.2021.658428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658428</ArticleId><ArticleId IdType="pmc">PMC8213020</ArticleId><ArticleId IdType="pubmed">34149696</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey K.E., Shah N., Misdraji J., Abu Dayyeh B.K., Zheng H., Bhan A.K., Chung R.T. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009;29:748&#x2013;753. doi: 10.1111/j.1478-3231.2009.01973.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2009.01973.x</ArticleId><ArticleId IdType="pmc">PMC3151254</ArticleId><ArticleId IdType="pubmed">19220742</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasa S., Burdo T.H., Williams K.C., Mitten E.K., Wong K., Fitch K.V., Stanley T., Adler G.K., Grinspoon S.K. Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices During HIV Infection. J. Infect. Dis. 2016;214:1336&#x2013;1340. doi: 10.1093/infdis/jiw392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw392</ArticleId><ArticleId IdType="pmc">PMC5079375</ArticleId><ArticleId IdType="pubmed">27549584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Chen S., Zhou G., Jin Y., Zhang R., Yang H., Xi Y., Ren J., Duan G. Involvement of the renin-angiotensin system in the progression of severe hand-foot-and-mouth disease. PLoS ONE. 2018;13:e0197861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965884</ArticleId><ArticleId IdType="pubmed">29791486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingraham N.E., Barakat A.G., Reilkoff R., Bezdicek T., Schacker T., Chipman J.G., Tignanelli C.J., Puskarich M.A. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: A comprehensive review. Eur. Respir. J. 2020;56:2000912. doi: 10.1183/13993003.00912-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00912-2020</ArticleId><ArticleId IdType="pmc">PMC7236830</ArticleId><ArticleId IdType="pubmed">32341103</ArticleId></ArticleIdList></Reference><Reference><Citation>Crajoinas R.O., Polidoro J.Z., Carneiro de Morais C.P., Castelo-Branco R.C., Girardi A.C. Angiotensin II counteracts the effects of cAMP/PKA on NHE3 activity and phosphorylation in proximal tubule cells. Am. J. Physiol. Cell Physiol. 2016;311:C768&#x2013;C776. doi: 10.1152/ajpcell.00191.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00191.2016</ArticleId><ArticleId IdType="pubmed">27510906</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 2006;20:953&#x2013;970. doi: 10.1210/me.2004-0536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2004-0536</ArticleId><ArticleId IdType="pubmed">16141358</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S., Rauf A., Khan H., Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed. Pharmacother. 2017;94:317&#x2013;325. doi: 10.1016/j.biopha.2017.07.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.07.091</ArticleId><ArticleId IdType="pubmed">28772209</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweda F., Friis U., Wagner C., Skott O., Kurtz A. Renin release. Physiology. 2007;22:310&#x2013;319. doi: 10.1152/physiol.00024.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00024.2007</ArticleId><ArticleId IdType="pubmed">17928544</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A., Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin. Exp. Nephrol. 2018;22:1231&#x2013;1239. doi: 10.1007/s10157-018-1567-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-018-1567-1</ArticleId><ArticleId IdType="pmc">PMC6163102</ArticleId><ArticleId IdType="pubmed">29600408</ArticleId></ArticleIdList></Reference><Reference><Citation>Emdin M., Fatini C., Mirizzi G., Poletti R., Borrelli C., Prontera C., Latini R., Passino C., Clerico A., Vergaro G. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible? Clin. Chim. Acta. 2015;443:85&#x2013;93. doi: 10.1016/j.cca.2014.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2014.10.031</ArticleId><ArticleId IdType="pubmed">25445411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cure E., Ilcol T.B., Cumhur Cure M. Angiotensin II, III, and IV may be important in the progression of COVID-19. J. Renin Angiotensin Aldosterone Syst. 2020;21:1470320320972019. doi: 10.1177/1470320320972019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320320972019</ArticleId><ArticleId IdType="pmc">PMC7658520</ArticleId><ArticleId IdType="pubmed">33169633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P.K., Griendling K.K. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007;292:C82&#x2013;C97. doi: 10.1152/ajpcell.00287.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00287.2006</ArticleId><ArticleId IdType="pubmed">16870827</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai D.F., Johnson S.C., Villarin J.J., Chin M.T., Nieves-Cintr&#xf3;n M., Chen T., Marcinek D.J., Dorn G.W., Kang Y.J., Prolla T.A., et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and G&#x3b1;q overexpression-induced heart failure. Circ. Res. 2011;108:837&#x2013;846. doi: 10.1161/CIRCRESAHA.110.232306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.110.232306</ArticleId><ArticleId IdType="pmc">PMC3785241</ArticleId><ArticleId IdType="pubmed">21311045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Hu R., Zhang C., Ren W., Yu A., Zhou X. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit. Care. 2020;24:290. doi: 10.1186/s13054-020-03015-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03015-0</ArticleId><ArticleId IdType="pmc">PMC7273814</ArticleId><ArticleId IdType="pubmed">32503680</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong H., Li X., Ma L., Jiang H., Mao Y., Xu M. Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation. J. Thorac. Cardiovasc. Surg. 2010;140:298&#x2013;304. doi: 10.1016/j.jtcvs.2009.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.10.035</ArticleId><ArticleId IdType="pubmed">20080265</ArticleId></ArticleIdList></Reference><Reference><Citation>Coromilas E.J., Kochav S., Goldenthal I., Biviano A., Garan H., Goldbarg S., Kim J.-H., Yeo I., Tracy C., Ayanian S., et al. Worldwide Survey of COVID-19-Associated Arrhythmias. Circ. Arrhythmia Electrophysiol. 2021;14:285&#x2013;295. doi: 10.1161/CIRCEP.120.009458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.120.009458</ArticleId><ArticleId IdType="pmc">PMC7982128</ArticleId><ArticleId IdType="pubmed">33554620</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustino G., Croft L.B., Stefanini G.G., Bragato R., Silbiger J.J., Vicenzi M., Danilov T., Kukar N., Shaban N., Kini A., et al. Characterization of Myocardial Injury in Patients with COVID-19. J. Am. Coll. Cardiol. 2020;76:2043&#x2013;2055. doi: 10.1016/j.jacc.2020.08.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.08.069</ArticleId><ArticleId IdType="pmc">PMC7588179</ArticleId><ArticleId IdType="pubmed">33121710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.F., Cheng W.H., Hung Y., Lin W.Y., Chao T.F., Liao J.N., Lin Y.J., Lin W.S., Chen Y.J., Chen S.A. Management of Atrial Fibrillation in COVID-19 Pandemic. Circ. J. 2020;84:1679&#x2013;1685. doi: 10.1253/circj.CJ-20-0566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-20-0566</ArticleId><ArticleId IdType="pubmed">32908073</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutanto H., Lyon A., Lumens J., Schotten U., Dobrev D., Heijman J. Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies. Prog. Biophys. Mol. Biol. 2020;157:54&#x2013;75. doi: 10.1016/j.pbiomolbio.2020.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2020.02.008</ArticleId><ArticleId IdType="pubmed">32188566</ArticleId></ArticleIdList></Reference><Reference><Citation>Namkung Y., LeGouill C., Kumar S., Cao Y., Teixeira L.B., Lukasheva V., Giubilaro J., Sim&#xf5;es S.C., Longpr&#xe9; J.M., Devost D., et al. Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. Sci. Signal. 2018;11:eaat1631. doi: 10.1126/scisignal.aat1631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aat1631</ArticleId><ArticleId IdType="pubmed">30514808</ArticleId></ArticleIdList></Reference><Reference><Citation>Porrello E.R., Delbridge L.M., Thomas W.G. The angiotensin II type 2 (AT2) receptor: An enigmatic seven transmembrane receptor. Front. Biosci. 2009;14:958&#x2013;972. doi: 10.2741/3289.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3289</ArticleId><ArticleId IdType="pubmed">19273111</ArticleId></ArticleIdList></Reference><Reference><Citation>Asada H., Inoue A., Ngako Kadji F.M., Hirata K., Shiimura Y., Im D., Shimamura T., Nomura N., Iwanari H., Hamakubo T., et al. The Crystal Structure of Angiotensin II Type 2 Receptor with Endogenous Peptide Hormone. Structure. 2020;28:418&#x2013;425.e4. doi: 10.1016/j.str.2019.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2019.12.003</ArticleId><ArticleId IdType="pubmed">31899086</ArticleId></ArticleIdList></Reference><Reference><Citation>Turu G., Szidonya L., G&#xe1;borik Z., Buday L., Sp&#xe4;t A., Clark A.J., Hunyady L. Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett. 2006;580:41&#x2013;45. doi: 10.1016/j.febslet.2005.11.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2005.11.044</ArticleId><ArticleId IdType="pubmed">16359671</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira L.B., Parreiras-E-Silva L.T., Bruder-Nascimento T., Duarte D.A., Sim&#xf5;es S.C., Costa R.M., Rodr&#xed;guez D.Y., Ferreira P.A.B., Silva C.A.A., Abrao E.P., et al. Ang-(1-7) is an endogenous &#x3b2;-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy. Sci. Rep. 2017;7:11903. doi: 10.1038/s41598-017-12074-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-12074-3</ArticleId><ArticleId IdType="pmc">PMC5605686</ArticleId><ArticleId IdType="pubmed">28928410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A.J., Santos R.A., Bradford C.N., Mecca A.P., Sumners C., Katovich M.J., Raizada M.K. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55:207&#x2013;213. doi: 10.1161/HYPERTENSIONAHA.109.140145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.140145</ArticleId><ArticleId IdType="pmc">PMC2826213</ArticleId><ArticleId IdType="pubmed">20038757</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., Campos M.M. Kinin B1 receptors: Key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J. Pharmacol. 2004;143:803&#x2013;818. doi: 10.1038/sj.bjp.0706012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0706012</ArticleId><ArticleId IdType="pmc">PMC1575942</ArticleId><ArticleId IdType="pubmed">15520046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii T., Onohara N., Maruyama Y., Tanabe S., Kobayashi H., Fukutomi M., Nagamatsu Y., Nishihara N., Inoue R., Sumimoto H., et al. Galpha12/13-mediated production of reactive oxygen species is critical for angiotensin receptor-induced NFAT activation in cardiac fibroblasts. J. Biol. Chem. 2005;280:23041&#x2013;23047. doi: 10.1074/jbc.M409397200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409397200</ArticleId><ArticleId IdType="pubmed">15826947</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatanawi A., Romero M.J., Iddings J.A., Chandra S., Umapathy N.S., Verin A.D., Caldwell R.B., Caldwell R.W. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am. J. Physiol. Cell Physiol. 2011;300:C1181&#x2013;C1192. doi: 10.1152/ajpcell.00328.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00328.2010</ArticleId><ArticleId IdType="pmc">PMC3093945</ArticleId><ArticleId IdType="pubmed">21289285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y.M., Kuen D.S., Chung Y., Kurose H., Kim S.G. G&#x3b1;12/13 signaling in metabolic diseases. Exp. Mol. Med. 2020;52:896&#x2013;910. doi: 10.1038/s12276-020-0454-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-0454-5</ArticleId><ArticleId IdType="pmc">PMC7338450</ArticleId><ArticleId IdType="pubmed">32576930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba K., Vaidya A., Rainey W.E. Aging and Adrenal Aldosterone Production. Hypertension. 2018;71:218&#x2013;223. doi: 10.1161/HYPERTENSIONAHA.117.10391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.10391</ArticleId><ArticleId IdType="pmc">PMC5839673</ArticleId><ArticleId IdType="pubmed">29229745</ArticleId></ArticleIdList></Reference><Reference><Citation>Maning J., Negussie S., Clark M.A., Lymperopoulos A. Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy. Pharmacol. Res. 2017;125:14&#x2013;20. doi: 10.1016/j.phrs.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.05.009</ArticleId><ArticleId IdType="pubmed">28511989</ArticleId></ArticleIdList></Reference><Reference><Citation>Monticone S., Burrello J., Tizzani D., Bertello C., Viola A., Buffolo F., Gabetti L., Mengozzi G., Williams T.A., Rabbia F., et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J. Am. Coll. Cardiol. 2017;69:1811&#x2013;1820. doi: 10.1016/j.jacc.2017.01.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.01.052</ArticleId><ArticleId IdType="pubmed">28385310</ArticleId></ArticleIdList></Reference><Reference><Citation>Funder J.W. Aldosterone and Mineralocorticoid Receptors-Physiology and Pathophysiology. Int. J. Mol. Sci. 2017;18:1032. doi: 10.3390/ijms18051032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18051032</ArticleId><ArticleId IdType="pmc">PMC5454944</ArticleId><ArticleId IdType="pubmed">28492512</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Li X.H., Yuan H. Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc. Diagn. Ther. 2012;2:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839167</ArticleId><ArticleId IdType="pubmed">24282697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaschina E., Namsolleck P., Unger T. AT2 receptors in cardiovascular and renal diseases. Pharmacol. Res. 2017;125:39&#x2013;47. doi: 10.1016/j.phrs.2017.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.07.008</ArticleId><ArticleId IdType="pubmed">28694144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp B.A., Howell N.L., Keller S.R., Gildea J.J., Padia S.H., Carey R.M. AT2 Receptor Activation Prevents Sodium Retention and Reduces Blood Pressure in Angiotensin II-Dependent Hypertension. Circ. Res. 2016;119:532&#x2013;543. doi: 10.1161/CIRCRESAHA.116.308384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.308384</ArticleId><ArticleId IdType="pmc">PMC4975636</ArticleId><ArticleId IdType="pubmed">27323774</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez L., Novoa U., Moya J., Gabrielli L., Jalil J.E., Garc&#xed;a L., Chiong M., Lavandero S., Ocaranza M.P. Angiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension. Biochem. Pharmacol. 2018;156:357&#x2013;370. doi: 10.1016/j.bcp.2018.08.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.08.045</ArticleId><ArticleId IdType="pubmed">30179588</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnik S.S., Singh K.D., Tirupula K., Unal H. Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. Br. J. Pharmacol. 2017;174:737&#x2013;753. doi: 10.1111/bph.13742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13742</ArticleId><ArticleId IdType="pmc">PMC5387002</ArticleId><ArticleId IdType="pubmed">28194766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercure C., Yogi A., Callera G.E., Aranha A.B., Bader M., Ferreira A.J., Santos R.A., Walther T., Touyz R.M., Reudelhuber T.L. Angiotensin (1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res. 2008;103:1319&#x2013;1326. doi: 10.1161/CIRCRESAHA.108.184911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.108.184911</ArticleId><ArticleId IdType="pubmed">18845809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.S., Yeoh S.F., Long C.M. COVID-19: Critical Role of Angiotensin 1-7 in ACE2 Modulation. Ann. Acad. Med. Singap. 2020;49:398&#x2013;400. doi: 10.47102/Annals-acadmedsg.202085.</Citation><ArticleIdList><ArticleId IdType="doi">10.47102/Annals-acadmedsg.202085</ArticleId><ArticleId IdType="pubmed">32712639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidarov I., Adams J., Frazer J., Anthony T., Chen X., Gatlin J., Semple G., Unett D.J. Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor. Cell Signal. 2018;50:9&#x2013;24. doi: 10.1016/j.cellsig.2018.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2018.06.007</ArticleId><ArticleId IdType="pubmed">29928987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.H., Zhang Y.H., Dong X.F., Hao Q.Q., Zhou X.M., Yu Q.T., Li S.Y., Chen X., Tengbeh A.F., Dong B., et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm. Res. 2015;64:253&#x2013;260. doi: 10.1007/s00011-015-0805-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-015-0805-1</ArticleId><ArticleId IdType="pubmed">25721616</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA. 2003;100:8258&#x2013;8263. doi: 10.1073/pnas.1432869100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1432869100</ArticleId><ArticleId IdType="pmc">PMC166216</ArticleId><ArticleId IdType="pubmed">12829792</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvin M.R., Alvarez C., Miller J.I., Prates E.T., Walker A.M., Amos B.K., Mast A.E., Justice A., Aronow B., Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife. 2020;9:e59177. doi: 10.7554/eLife.59177.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59177</ArticleId><ArticleId IdType="pmc">PMC7410499</ArticleId><ArticleId IdType="pubmed">32633718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancion A., Tridetti J., Nguyen Trung M.L., Oury C., Lancellotti P. A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril. Cardiol. Ther. 2019;8:179&#x2013;191. doi: 10.1007/s40119-019-00150-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40119-019-00150-w</ArticleId><ArticleId IdType="pmc">PMC6828891</ArticleId><ArticleId IdType="pubmed">31578675</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002;277:14838&#x2013;14843. doi: 10.1074/jbc.M200581200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M200581200</ArticleId><ArticleId IdType="pubmed">11815627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y., Prindle T., Fulton W.B., Wang S., McCray P.B., Jr., Chappell M., Hackam D.J., Jia H. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am. J. Physiol. Lung Cell Mol. Physiol. 2018;314:L17&#x2013;L31. doi: 10.1152/ajplung.00498.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00498.2016</ArticleId><ArticleId IdType="pmc">PMC5866432</ArticleId><ArticleId IdType="pubmed">28935640</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. Researchers investigate what COVID-19 does to the heart. JAMA. 2021;325:808&#x2013;811. doi: 10.1001/jama.2021.0107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0107</ArticleId><ArticleId IdType="pubmed">33566089</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhenc-Gelas F., Bouby N., Girolami J.-P. Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in disease insight from human and experimental genetic studies, therapeutic Implication. Front. Med. 2019;6:136. doi: 10.3389/fmed.2019.00136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2019.00136</ArticleId><ArticleId IdType="pmc">PMC6610447</ArticleId><ArticleId IdType="pubmed">31316987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceconi C., Francolini G., Olivares A., Comini L., Bachetti T., Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007;577:1&#x2013;6. doi: 10.1016/j.ejphar.2007.07.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2007.07.061</ArticleId><ArticleId IdType="pubmed">17716647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyne S., Pyne N.J. Differential effects of B2 receptor antagonists upon bradykinin-stimulated phospholipase C and D in guinea-pig cultured tracheal smooth muscle. Br. J. Pharmacol. 1993;110:477&#x2013;481. doi: 10.1111/j.1476-5381.1993.tb13835.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.1993.tb13835.x</ArticleId><ArticleId IdType="pmc">PMC2175983</ArticleId><ArticleId IdType="pubmed">8220910</ArticleId></ArticleIdList></Reference><Reference><Citation>Radonjic-Hoesli S., Hofmeier K.S., Micaletto S., Micaletto S., Schmid-Grendelmeier P., Bircher A., Simon D. Urticaria and Angioedema: An Update on Classification and Pathogenesis. Clin. Rev. Allerg. Immunol. 2018;54:88&#x2013;101. doi: 10.1007/s12016-017-8628-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-017-8628-1</ArticleId><ArticleId IdType="pubmed">28748365</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Veerdonk F.L., Netea M.G., van Deuren M., van der Meer J.W.M., de Mast Q., Br&#xfc;ggemann R.J., van der Hoeven H. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. 2020;9:e57555. doi: 10.7554/eLife.57555.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.57555</ArticleId><ArticleId IdType="pmc">PMC7213974</ArticleId><ArticleId IdType="pubmed">32338605</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Ren L., Zhang L., Zhong J., Xiao Y., Jia Z., Guo L., Yang J., Wang C., Jiang S., et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe. 2020;27:883&#x2013;890. doi: 10.1016/j.chom.2020.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., Cheng L., Li J., Wang X., Wang F., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842&#x2013;844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff B.J., Ram&#xed;rez-Su&#xe1;stegui C., Fajardo V., Chee S.J., Kusnadi A., Simon H., Eschweiler S., Grifoni A., Pelosi E., Weiskopf D., et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell. 2020;183:1340&#x2013;1353. doi: 10.1016/j.cell.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637&#x2013;650. doi: 10.1016/j.immuni.2011.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.05.006</ArticleId><ArticleId IdType="pubmed">21616434</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Narazaki M., Kishimoto T. Il-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014;6:a016295. doi: 10.1101/cshperspect.a016295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId><ArticleId IdType="pmc">PMC4176007</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez-Salinas L., Verdugo-Rodriguez A., Rodriguez L.L., Borca M.V. The role of interleukin 6 during viral infections. Front. Microbiol. 2019;10:1057. doi: 10.3389/fmicb.2019.01057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01057</ArticleId><ArticleId IdType="pmc">PMC6524401</ArticleId><ArticleId IdType="pubmed">31134045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircheis R., Haasbach E., Lueftenegger D., Heyken W.T., Ocker M., Planz O. NF-&#x3ba;B pathway as a potential target for treatment of critical stage COVID-19 patients. Front. Immunol. 2020;11:598444. doi: 10.3389/fimmu.2020.598444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.598444</ArticleId><ArticleId IdType="pmc">PMC7759159</ArticleId><ArticleId IdType="pubmed">33362782</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones S.A., Jenkins B.J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 2018;18:773&#x2013;789. doi: 10.1038/s41577-018-0066-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0066-7</ArticleId><ArticleId IdType="pubmed">30254251</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J.H., Liu Y.X., Yuan J., Wang F.X., Wu W.B., Li J.X., Wang L.F., Gao H., Wang Y., Dong C.F., et al. First case of COVID-19 complicated with fulminant myocarditis: A case report and insights. Infection. 2020;48:773&#x2013;777. doi: 10.1007/s15010-020-01424-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-020-01424-5</ArticleId><ArticleId IdType="pmc">PMC7146072</ArticleId><ArticleId IdType="pubmed">32277408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;5:811&#x2013;818. doi: 10.1001/jamacardio.2020.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao S.C., Shao S.C., Cheng C.W., Chen Y.C., Hung M.J. Incidence rate and clinical impacts of arrhythmia following COVID-19: A systematic review and meta-analysis of 17,435 patients. Crit. Care. 2020;24:690. doi: 10.1186/s13054-020-03368-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03368-6</ArticleId><ArticleId IdType="pmc">PMC7727094</ArticleId><ArticleId IdType="pubmed">33302973</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse G., Yeo J.M., Chan Y.W., Lai E.T.H.L., Yan B.P. What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies. Front. Physiol. 2016;7:308. doi: 10.3389/fphys.2016.00308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2016.00308</ArticleId><ArticleId IdType="pmc">PMC4954848</ArticleId><ArticleId IdType="pubmed">27493633</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander L.K., Keene B.W., Small J.D., Yount B., Baric R.S. Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy. Adv. Exp. Med. Biol. 1993;342:365&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertanto D.M., Sutanto H., Wiratama B.S., Wungu C.D.K. Modulating the host immune response to fight against COVID-19: Where are we in 2021? Virulence. 2021;12:1732&#x2013;1736. doi: 10.1080/21505594.2021.1943275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2021.1943275</ArticleId><ArticleId IdType="pmc">PMC8259726</ArticleId><ArticleId IdType="pubmed">34224330</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone F., Piccirillo M.C., Ascierto P.A., Salvarani C., Parrella R., Marata A.M., Popoli P., Ferraris L., Marrocco-Trischitta M.M., Ripamonti D., et al. TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J. Transl. Med. 2020;18:405. doi: 10.1186/s12967-020-02573-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02573-9</ArticleId><ArticleId IdType="pmc">PMC7576974</ArticleId><ArticleId IdType="pubmed">33087150</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee B., Thakur S.S. ACE2 as a potential therapeutic target for pandemic COVID-19. RSC Adv. 2020;10:39808&#x2013;39813. doi: 10.1039/D0RA08228G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0RA08228G</ArticleId><ArticleId IdType="pmc">PMC9057484</ArticleId><ArticleId IdType="pubmed">35515386</ArticleId></ArticleIdList></Reference><Reference><Citation>Campana P., Flocco V., Aruta F., Cacciatore F., Abete P. Can aldosterone increase interleukin-6 levels in COVID-19 pneumonia? J. Med. Virol. 2021;93:622&#x2013;623. doi: 10.1002/jmv.26382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26382</ArticleId><ArticleId IdType="pmc">PMC7436813</ArticleId><ArticleId IdType="pubmed">32749708</ArticleId></ArticleIdList></Reference><Reference><Citation>Terenzi R., Manetti M., Rosa I., Romano E., Galluccio F., Guiducci S., Ibba-Manneschi L., Matucci-Cerinic M. Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. Sci. Rep. 2017;7:13293. doi: 10.1038/s41598-017-13746-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13746-w</ArticleId><ArticleId IdType="pmc">PMC5643391</ArticleId><ArticleId IdType="pubmed">29038523</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscella A., Cossa L.G., Vetrugno C., Marsigliante S. Bradykinin stimulates prostaglandin E2 release in human skeletal muscular fibroblasts. Mol. Cell. Endocrinol. 2020;507:110771. doi: 10.1016/j.mce.2020.110771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2020.110771</ArticleId><ArticleId IdType="pubmed">32114020</ArticleId></ArticleIdList></Reference><Reference><Citation>Colarusso C., Terlizzi M., Pinto A., Sorrentino R. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Br. J. Pharmacol. 2020;177:4866&#x2013;4872. doi: 10.1111/bph.15154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15154</ArticleId><ArticleId IdType="pmc">PMC7300552</ArticleId><ArticleId IdType="pubmed">32497257</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl M.A., Maurer M., Bernstein J.A., Banerji A., Longhurst H.J., Li H.H., Lu P., Hao J., Juethner S., Lumry W.R., et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020;75:2879&#x2013;2887. doi: 10.1111/all.14416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14416</ArticleId><ArticleId IdType="pmc">PMC7689768</ArticleId><ArticleId IdType="pubmed">32452549</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd J.B., Touzin K., Sile S., Gainer J.V., Yu C., Nadeau J., Adam A., Brown N.J. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema. Hypertension. 2008;51:141&#x2013;147. doi: 10.1161/HYPERTENSIONAHA.107.096552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.107.096552</ArticleId><ArticleId IdType="pmc">PMC2749928</ArticleId><ArticleId IdType="pubmed">18025295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulbricht D., Tindall C.A., Oertwig K., Hanke S., Str&#xe4;ter N., Heiker J.T. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin. Biol. Chem. 2018;399:1079&#x2013;1084. doi: 10.1515/hsz-2018-0108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2018-0108</ArticleId><ArticleId IdType="pubmed">29494334</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Veerdonk F., Janssen N., Grondman I., de Nooijer A., Koeken V., Matzaraki V., Boahen C., Kumar V., Kox M., Koenen H., et al. A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection. medRxiv. 2020;2:100166.</Citation></Reference><Reference><Citation>Dawson P., Rabold E.M., Laws R.L., Conners E.E., Gharpure R., Yin S., Buono S.A., Dasu T., Bhattacharyya S., Westergaard R.P., et al. Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019. Clin. Infect. Dis. 2021;72:682&#x2013;685. doi: 10.1093/cid/ciaa799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa799</ArticleId><ArticleId IdType="pmc">PMC7337666</ArticleId><ArticleId IdType="pubmed">32562541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmudpour M., Roozbeh J., Keshavarz M., Farrokhi S., Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151. doi: 10.1016/j.cyto.2020.155151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155151</ArticleId><ArticleId IdType="pmc">PMC7260598</ArticleId><ArticleId IdType="pubmed">32544563</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Covassin N., Fan Z., Singh P., Gao W., Li G., Kara T., Somers V.K. Association Between Hypoxemia and Mortality in Patients with COVID-19. Mayo Clin. Proc. 2020;95:1138&#x2013;1147. doi: 10.1016/j.mayocp.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.04.006</ArticleId><ArticleId IdType="pmc">PMC7151468</ArticleId><ArticleId IdType="pubmed">32376101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdery A.M., Newmyer L., Wagner B., Margolis R. National Profiles of Coronavirus Disease 2019 Mortality Risks by Age Structure and Pre-existing Health Conditions. Gerontologist. 2021;61:71&#x2013;77. doi: 10.1093/geront/gnaa152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/gnaa152</ArticleId><ArticleId IdType="pmc">PMC7665488</ArticleId><ArticleId IdType="pubmed">33030209</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis D., Barish M.A., Goldin M., Cohen S.L., Kohn N., Gianos E., Chatterjee S., Lesser M., Coppa K., Hirsch J.S., et al. Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. J. Thromb. Thrombolysis. 2021;51:897&#x2013;901. doi: 10.1007/s11239-021-02413-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02413-7</ArticleId><ArticleId IdType="pmc">PMC7932762</ArticleId><ArticleId IdType="pubmed">33665766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., Der Nigoghossian C., Ageno W., Madjid M., Guo Y., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020;75:2950&#x2013;2973. doi: 10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:1421&#x2013;1424. doi: 10.1111/jth.14830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14830</ArticleId><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., Merdji H., Clere-Jehl R., Schenck M., Gandet F.F., et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020;46:1089&#x2013;1098. doi: 10.1007/s00134-020-06062-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner W.J., Kanji R., Mirsadraee S., Gue Y.X., Price S., Prasad S., Gorog D.A. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: A systematic review. J. Thromb. Thrombolysis. 2021;51:595&#x2013;607. doi: 10.1007/s11239-021-02394-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02394-7</ArticleId><ArticleId IdType="pmc">PMC7882250</ArticleId><ArticleId IdType="pubmed">33586113</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb. Res. 2020;191:148&#x2013;150. doi: 10.1016/j.thromres.2020.04.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.041</ArticleId><ArticleId IdType="pmc">PMC7192101</ArticleId><ArticleId IdType="pubmed">32381264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Paz L., Capodanno D., Montalescot G., Angiolillo D. COVID-19 Associated Thrombosis and Coagulopathy: Review of the Pathophysiology and Implications for Antithrombotic Management. J. Am. Heart Assoc. 2021;10:e019650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955431</ArticleId><ArticleId IdType="pubmed">33228447</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C.S., Nabar N.R., Huang N.N., Kehrl J.H. SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101. doi: 10.1038/s41420-019-0181-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-019-0181-7</ArticleId><ArticleId IdType="pmc">PMC6549181</ArticleId><ArticleId IdType="pubmed">31231549</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson K.V., Deng M., Ting J.P.Y. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019;19:477&#x2013;489. doi: 10.1038/s41577-019-0165-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0165-0</ArticleId><ArticleId IdType="pmc">PMC7807242</ArticleId><ArticleId IdType="pubmed">31036962</ArticleId></ArticleIdList></Reference><Reference><Citation>Savla S.R., Prabhavalkar K.S., Bhatt L.K. Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. Expert Rev. Anti-Infect. Ther. 2021 doi: 10.1080/14787210.2021.1915129. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1915129</ArticleId><ArticleId IdType="pmc">PMC8074652</ArticleId><ArticleId IdType="pubmed">33832398</ArticleId></ArticleIdList></Reference><Reference><Citation>Page E.M., Ari&#xeb;ns R.A.S. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb. Res. 2021;200:1&#x2013;8. doi: 10.1016/j.thromres.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7813504</ArticleId><ArticleId IdType="pubmed">33493983</ArticleId></ArticleIdList></Reference><Reference><Citation>Dmitrieva N.I., Burg M.B. Elevated Sodium and Dehydration Stimulate Inflammatory Signaling in Endothelial Cells and Promote Atherosclerosis. PLoS ONE. 2015;10:e0128870. doi: 10.1371/journal.pone.0128870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0128870</ArticleId><ArticleId IdType="pmc">PMC4456159</ArticleId><ArticleId IdType="pubmed">26042828</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., De Marco G., Bridgewood C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J. Autoimmun. 2021;121:102662. doi: 10.1016/j.jaut.2021.102662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102662</ArticleId><ArticleId IdType="pmc">PMC8133385</ArticleId><ArticleId IdType="pubmed">34051613</ArticleId></ArticleIdList></Reference><Reference><Citation>Billy E., Clarot F., Depagne C., Korsia-Meffre S., Rochoy M., Zores F. Thrombotic events after AstraZeneca vaccine: What if it was related to dysfunctional immune response? Therapie. 2021 doi: 10.1016/j.therap.2021.04.003. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8057862</ArticleId><ArticleId IdType="pubmed">33892936</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., et al. COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574&#x2013;1581. doi: 10.1001/jama.2020.5394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5394</ArticleId><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Grant M.B., Richards E.M., Raizada M.K. ACE2 as therapeutic agent. Clin. Sci. 2020;134:2581&#x2013;2595. doi: 10.1042/CS20200570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200570</ArticleId><ArticleId IdType="pubmed">33063820</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds H.R., Adhikari S., Pulgarin C., Troxel A.B., Iturrate E., Johnson S.B., Hausvater A., Newman J.D., Berger J.S., Bangalore S., et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. N. Engl. J. Med. 2020;382:2441&#x2013;2448. doi: 10.1056/NEJMoa2008975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2008975</ArticleId><ArticleId IdType="pmc">PMC7206932</ArticleId><ArticleId IdType="pubmed">32356628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosso M., Thanaraj T.A., Abu-Farha M., Alanbaei M., Abubaker J., Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol. Ther. Methods Clin. Dev. 2020;18:321&#x2013;327. doi: 10.1016/j.omtm.2020.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7314689</ArticleId><ArticleId IdType="pubmed">32665962</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux C.A., Rolain J.-M., Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Immunol. Infect. 2020;53:425&#x2013;435. doi: 10.1016/j.jmii.2020.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.04.015</ArticleId><ArticleId IdType="pmc">PMC7201239</ArticleId><ArticleId IdType="pubmed">32414646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseinzadeh R., Goharrizi M.A.S.B., Bahardoust M., Alvanegh A.G., Ataee M.R., Bagheri M., Navidiyan E.S., Zijoud S.R.H., Heiat M. Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)? Clin. Hypertens. 2021;27:3. doi: 10.1186/s40885-021-00161-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-021-00161-7</ArticleId><ArticleId IdType="pmc">PMC7809228</ArticleId><ArticleId IdType="pubmed">33451360</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond G.R., Vinh A., Guzik T.J., Sobey C.G. Immune mechanisms of hypertension. Nat. Rev. Immunol. 2019;19:517&#x2013;532. doi: 10.1038/s41577-019-0160-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0160-5</ArticleId><ArticleId IdType="pubmed">30992524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjeldsen S.E. Hypertension and cardiovascular risk: General aspects. Pharmacol. Res. 2018;129:95&#x2013;99. doi: 10.1016/j.phrs.2017.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.11.003</ArticleId><ArticleId IdType="pubmed">29127059</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss P., Murdoch D.R. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395:1014&#x2013;1015. doi: 10.1016/S0140-6736(20)30633-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30633-4</ArticleId><ArticleId IdType="pmc">PMC7138151</ArticleId><ArticleId IdType="pubmed">32197108</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H., Liu Q., Xi M., Xiong D., He J., Luo P., Li Z., Third W., Hospital W.T. Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19. J. Investig. Med. 2021;69:75&#x2013;85. doi: 10.1136/jim-2020-001555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2020-001555</ArticleId><ArticleId IdType="pmc">PMC7554406</ArticleId><ArticleId IdType="pubmed">33051358</ArticleId></ArticleIdList></Reference><Reference><Citation>Savoia C., Volpe M., Kreutz R. Hypertension, a moving target in COVID-19: Current views and perspectives. Circ. Res. 2021;128:1062&#x2013;1079. doi: 10.1161/CIRCRESAHA.121.318054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318054</ArticleId><ArticleId IdType="pmc">PMC8011346</ArticleId><ArticleId IdType="pubmed">33793331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Li X., Chen M., Feng Y., Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc. Res. 2020;116:1097&#x2013;1100. doi: 10.1093/cvr/cvaa078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa078</ArticleId><ArticleId IdType="pmc">PMC7184507</ArticleId><ArticleId IdType="pubmed">32227090</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley L.F., Cheng J.W.M., Desai A. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. J. Cardiovasc. Pharmacol. 2020;75:526&#x2013;529. doi: 10.1097/FJC.0000000000000840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000840</ArticleId><ArticleId IdType="pmc">PMC7219856</ArticleId><ArticleId IdType="pubmed">32301766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai H., Kai M., Niiyama H., Okina N., Sasaki M., Maeda T., Katoh A. Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies. Hypertens. Res. 2021 doi: 10.1038/s41440-021-00641-1. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-021-00641-1</ArticleId><ArticleId IdType="pmc">PMC7943405</ArticleId><ArticleId IdType="pubmed">33750913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow C.S., Ming L.C., Hasan S.S. Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. Hypertens. Res. 2021 doi: 10.1038/s41440-021-00670-w. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-021-00670-w</ArticleId><ArticleId IdType="pmc">PMC8134827</ArticleId><ArticleId IdType="pubmed">34017093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae S.A., Kim S.R., Kim M.N., Shim W.J., Park S.M. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: A systematic review and meta-analysis. Heart. 2021;107:373&#x2013;380. doi: 10.1136/heartjnl-2020-317901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2020-317901</ArticleId><ArticleId IdType="pubmed">33334865</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R., Huang I., Lim M.A., Wahjoepramono E.J., July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19&#x2013;systematic review, meta-analysis, and meta-regression. J. Stroke Cerebrovasc. Dis. 2020;29:104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2020.104949</ArticleId><ArticleId IdType="pmc">PMC7221373</ArticleId><ArticleId IdType="pubmed">32410807</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar S., Benter I.F., Danjuma M.I., Doi S.A.R., Hasan S.S., Habib A.M. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety. J. Drug Target. 2020;28:683&#x2013;699. doi: 10.1080/1061186X.2020.1797754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1061186X.2020.1797754</ArticleId><ArticleId IdType="pubmed">32700580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostal D.E., Hunt R.A., Kule C.E., Bhat G.J., Karoor V., McWhinney C.D., Baker K.M. Molecular mechanisms of angiotensin II in modulating cardiac function: Intracardiac effects and signal transduction pathways. J. Mol. Cell Cardiol. 1997;29:2893&#x2013;2902. doi: 10.1006/jmcc.1997.0524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmcc.1997.0524</ArticleId><ArticleId IdType="pubmed">9405164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascolo A., Urbanek K., De Angelis A., Sessa M., Scavone C., Berrino L., Rosano G.M.C., Capuano A., Rossi F. Angiotensin II and angiotensin 1-7: Which is their role in atrial fibrillation? Heart Fail. Rev. 2020;25:367&#x2013;380. doi: 10.1007/s10741-019-09837-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-019-09837-7</ArticleId><ArticleId IdType="pubmed">31375968</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurino A., Spinelli V., Gencarelli M., Balducci V., Dini L., Diolaiuti L., Ghionzoli M., Messineo A., Mugelli A., Cerbai E., et al. Angiotensin-II Drives Human Satellite Cells Toward Hypertrophy and Myofibroblast Trans-Differentiation by Two Independent Pathways. Int. J. Mol. Sci. 2019;20:4912. doi: 10.3390/ijms20194912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20194912</ArticleId><ArticleId IdType="pmc">PMC6801484</ArticleId><ArticleId IdType="pubmed">31623362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceravolo G.S., Montezano A.C., Jord&#xe3;o M.T., Akamine E.H., Costa T.J., Takano A.P., Fernandes D.C., Barreto-Chaves M.L., Laurindo F.R., Tostes R.C., et al. An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: In vivo and in vitro studies. PLoS ONE. 2014;9:e111117110. doi: 10.1371/journal.pone.0111117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111117</ArticleId><ArticleId IdType="pmc">PMC4219703</ArticleId><ArticleId IdType="pubmed">25369284</ArticleId></ArticleIdList></Reference><Reference><Citation>Skogestad J., Aronsen J.M. Hypokalemia-induced arrhythmias and heart failure: New insights and implications for therapy. Front. Physiol. 2018;9:1500. doi: 10.3389/fphys.2018.01500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.01500</ArticleId><ArticleId IdType="pmc">PMC6234658</ArticleId><ArticleId IdType="pubmed">30464746</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona G., Pizzocaro A., Vena W., Rastrelli G., Semeraro F., Isidori A.M., Pivonello R., Salonia A., Sforza A., Maggi M. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 2021;22:275&#x2013;2968. doi: 10.1007/s11154-021-09630-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-021-09630-8</ArticleId><ArticleId IdType="pmc">PMC7899074</ArticleId><ArticleId IdType="pubmed">33616801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., She Z.G., Cheng X., Qin J.J., Zhang X.J., Cai J., Lei F., Wang H., Xie J., Wang W., et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31:1068&#x2013;1077. doi: 10.1016/j.cmet.2020.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.04.021</ArticleId><ArticleId IdType="pmc">PMC7252168</ArticleId><ArticleId IdType="pubmed">32369736</ArticleId></ArticleIdList></Reference><Reference><Citation>Azar W.S., Njeim R., Fares A.H., Azar N.S., Azar S.T., El Sayed M., Eid A.A. COVID-19 and diabetes mellitus: How one pandemic worsens the other. Rev. Endocr. Metab. Disord. 2020;21:451&#x2013;463. doi: 10.1007/s11154-020-09573-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-020-09573-6</ArticleId><ArticleId IdType="pmc">PMC7395898</ArticleId><ArticleId IdType="pubmed">32743793</ArticleId></ArticleIdList></Reference><Reference><Citation>Apicella M., Campopiano M.C., Mantuano M., Mazoni L., Coppelli A., Del Prato S. COVID-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782&#x2013;792. doi: 10.1016/S2213-8587(20)30238-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30238-2</ArticleId><ArticleId IdType="pmc">PMC7367664</ArticleId><ArticleId IdType="pubmed">32687793</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsadhan I., Alruwashid S., Alhamad M., Alajmi S., Alshehri S., Alfadhli E., Ekhzaimy A. Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: Case series. Curr. Ther. Res. Clin. Exp. 2020;93:100609. doi: 10.1016/j.curtheres.2020.100609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.curtheres.2020.100609</ArticleId><ArticleId IdType="pmc">PMC7590633</ArticleId><ArticleId IdType="pubmed">33132404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X., Uhl S., Zhang T., Xue D., Li B., Vandana J.J., Acklin J.A., Bonnycastle L.L., Narisu N., Erdos M.R., et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021 doi: 10.1016/j.cmet.2021.05.015. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.015</ArticleId><ArticleId IdType="pmc">PMC8133495</ArticleId><ArticleId IdType="pubmed">34081913</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Long X., Zhang B., Zhang W., Chen X., Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage after SARS-CoV-2 Infection. Clin. Gastroenterol. Hepatol. 2020;18:2128&#x2013;2130. doi: 10.1016/j.cgh.2020.04.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.04.040</ArticleId><ArticleId IdType="pmc">PMC7194639</ArticleId><ArticleId IdType="pubmed">32334082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa I., Ishikawa M., Takahashi K., Watanabe M., Nishimaki K., Yamagata K., Katsura K., Katayama Y., Asoh S., Ohta S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 2007;13:688&#x2013;694. doi: 10.1038/nm1577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1577</ArticleId><ArticleId IdType="pubmed">17486089</ArticleId></ArticleIdList></Reference><Reference><Citation>Negre-Salvayre A., Salvayre R., Aug&#xe9; N., Pamplona R., Portero-Ot&#xed;n M. Hyperglycemia and Glycation in Diabetic Complications. Antioxid. Redox. Signal. 2009;11:3071&#x2013;3109. doi: 10.1089/ars.2009.2484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2009.2484</ArticleId><ArticleId IdType="pubmed">19489690</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe T., Egbuche O., Igwe J., Jegede O., Wagle B., Olanipekun T., Onwuanyi A. Cardiovascular complications in COVID-19 patients with or without diabetes mellitus. Endocrinol. Diabetes Metab. 2021;4:e00218. doi: 10.1002/edm2.218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/edm2.218</ArticleId><ArticleId IdType="pmc">PMC7883043</ArticleId><ArticleId IdType="pubmed">33614986</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis J.M., McGovern A.P., Vollmer S.J., Mateen B.A. Improving Survival of Critical Care Patients with Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020. Crit. Care Med. 2021;49:209&#x2013;214. doi: 10.1097/CCM.0000000000004747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004747</ArticleId><ArticleId IdType="pmc">PMC7803441</ArticleId><ArticleId IdType="pubmed">33105150</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M., Rayner C., Delaney B. Fresh evidence of the scale and scope of long COVID. BMJ. 2021;373:n853. doi: 10.1136/bmj.n853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n853</ArticleId><ArticleId IdType="pubmed">33795224</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin S.J., McIvor C., Whyatt G., Adams A., Harvey O., McLean L., Walshaw C., Kemp S., Corrado J., Singh R., et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol. 2021;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H., Patel K., Greenwood D.C., Halpin S., Lewthwaite P., Salawu A., Eyre L., Breen A., Jones A., Sivan M. Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. medRxiv. 2020 doi: 10.1101/2020.04.16.20067975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.16.20067975</ArticleId><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: A retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Kapur S., Alberts J., Badley A.D., Decker G.A., Rizza S.A., Banerjee R., Banerjee A. Multi-organ impairment in low-risk individuals with long COVID. medRxiv. 2020 doi: 10.1101/2020.10.14.20212555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.14.20212555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. Int. J. Paediatr. 2021;110:914&#x2013;921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Violin J.D., DeWire S.M., Yamashita D., Rominger D.H., Nguyen L., Schiller K., Whalen E.J., Gowen M., Lark M.W. Selectively engaging &#x3b2;-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 2010;335:572&#x2013;579. doi: 10.1124/jpet.110.173005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.110.173005</ArticleId><ArticleId IdType="pubmed">20801892</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscha Steckelings U., Sumners C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin. Sci. 2020;134:2987&#x2013;3006. doi: 10.1042/CS20200922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200922</ArticleId><ArticleId IdType="pubmed">33210709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathinasabapathy A., Horowitz A., Horton K., Kumar A., Gladson S., Unger T., Martinez D., Bedse G., West J., Raizada M.K., et al. The selective angiotensin II type 2 receptor agonist, compound 21, attenuates the progression of lung fibrosis and pulmonary hypertension in an experimental model of bleomycin-induced lung injury. Front. Physiol. 2018;9:180. doi: 10.3389/fphys.2018.00180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00180</ArticleId><ArticleId IdType="pmc">PMC5881224</ArticleId><ArticleId IdType="pubmed">29636695</ArticleId></ArticleIdList></Reference><Reference><Citation>Namsolleck P., Moll G.N. Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19? Mol. Med. 2020;26:80. doi: 10.1186/s10020-020-00211-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-020-00211-0</ArticleId><ArticleId IdType="pmc">PMC7430134</ArticleId><ArticleId IdType="pubmed">32807075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez Prada J.A., Ferreira A.J., Katovich M.J., Shenoy V., Qi Y., Santos R.A.S., Castellano R.K., Lampkins A.J., Gubala V., Ostrov D.A., et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312&#x2013;1317. doi: 10.1161/HYPERTENSIONAHA.107.108944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.107.108944</ArticleId><ArticleId IdType="pubmed">18391097</ArticleId></ArticleIdList></Reference><Reference><Citation>Prata L.O., Rodrigues C.R., Martins J.M., Vasconcelos P.C., Oliveira F.M.S., Ferreira A.J., Rodrigues-Machado M.d.G., Caliari M.V. Original Research: ACE2 activator associated with physical exercise potentiates the reduction of pulmonary fibrosis. Exp. Biol. Med. 2017;242:8&#x2013;21. doi: 10.1177/1535370216665174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370216665174</ArticleId><ArticleId IdType="pmc">PMC5206984</ArticleId><ArticleId IdType="pubmed">27550926</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Joshi S., Guo L., Baker M.B., Li Y., Castellano R.K., Raizada M.K., Jarajapu Yagna Y.P.R. ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am. J. Physiol. Hear. Circ. Physiol. 2015;309:H1697&#x2013;H1707. doi: 10.1152/ajpheart.00854.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00854.2014</ArticleId><ArticleId IdType="pmc">PMC4666983</ArticleId><ArticleId IdType="pubmed">26386115</ArticleId></ArticleIdList></Reference><Reference><Citation>Savergnini S.Q., Beiman M., Lautner R.Q., De Paula-Carvalho V., Allahdadi K., Caires Pessoa D., Pereira Costa-Fraga F., Ara&#xfa;jo Fraga-Silva R., Cojocaru G., Cohen Y., et al. Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor. Hypertension. 2010;56:112&#x2013;120. doi: 10.1161/HYPERTENSIONAHA.110.152942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.110.152942</ArticleId><ArticleId IdType="pubmed">20479330</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour E., Palma A.C., Ulaf R.G., Ribeiro L.C., Bernardes A.F., Nunes T.A., Agrela M.V., Bombassaro B., Monfort-Pires M., Camargo R.L., et al. Safety and outcomes associated with the pharmacological inhibition of the kinin&#x2013;kallikrein system in severe COVID-19. Viruses. 2021;13:309. doi: 10.3390/v13020309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020309</ArticleId><ArticleId IdType="pmc">PMC7920028</ArticleId><ArticleId IdType="pubmed">33669276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>